At the FLORetina Conference in Florence, Italy, John W. Kitchens, of Retina Associates of Kentucky, highlighted strategies to enhance efficiency in retina practices, addressing challenges like staff shortages and rising patient volumes. He emphasized streamlined workflows, advanced diagnostic tools, and enhanced patient communication to optimize care and improve outcomes.
In an interview with Ophthalmology Times, clinical trial investigator Zaina Al-Mohtaseb MD, noted the CLARA Phase 1/2 trial demonstrated the safety, efficacy, and simplicity of corneal endothelial cell injection therapy with a rho kinase inhibitor, offering a less invasive alternative to traditional corneal transplantation for treating corneal edema.
THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.
According to the company, its Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent efficacy, especially in the high-dose group, with favorable safety and tolerability profiles.
QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with RVO, including those with central, branch and hemiretinal vein occlusions.
This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.
The company is advancing its Phase I/II trial and exploring accelerated approval pathways in the US and Europe.
Research data published earlier this year could help clinicians gain a better understanding of what to look for in a specular microscope, and how to interpret inter- and intradevice repeatability results in a way that benefits their existing practice framework.
A global survey explores the impact of geographic atrophy (GA) on quality of life, revealing similar challenges for individuals with unilateral and bilateral GA. Researchers also highlight the need for improved education, support, and treatment options.
The EMA issued a positive opinion and recommendation for marketing authorization for Eydenzelt (biosimilar aflibercept).
In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging AAV.SPR capsid for central retina transduction without foveal detachment risks.
Researchers at the USC Ginsburg Institute for Biomedical Therapeutics and the USC Roski Eye Institute are advancing a new treatment for dry age-related macular degeneration, a leading cause of blindness in older adults.
The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.
USC is leading a research team aiming to better understand retinitis pigmentosa and inform future treatments.
This Week in Ophthalmology is a weekly video series highlighting some of the top articles and videos featured on the Ophthalmology Times website.
A study investigating the impact of socioeconomic status (SES) on open globe injury (OGI) found that lower SES, measured by the Social Vulnerability Index and Distressed Communities Index, correlates with younger age, non-accidental injuries, and poorer visual outcomes in OGI patients.
The 14th annual Glaucoma 360 conference, co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, will be held from February 6-8, 2025, at the Westin St. Francis in San Francisco, California. The event will focus on the latest advancements in glaucoma care and encourage innovation and collaboration.
Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP reduction, medication reduction, and a favorable safety profile, offering a promising new approach for open-angle glaucoma management.
The joint project AMD-HALT, pairs Amarna’s SV40-derived gene delivery vector platform with Phenocell’s in vitro AMD disease model, which accurately mimics cellular interactions and microenvironment of the retina
Researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of diabetic macular edema (DME).
Tenpoint Therapeutics and Visus Therapeutics have merged to focus on aging-related ocular conditions, with key products including BRIMOCHOL PF for presbyopia and therapies for cataracts and geographic atrophy.
In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.
A look at the latest advances from flash photography to AI-driven OCT
VisiRose, a company formed in collaboration with Provectus Biopharmaceuticals and the University of Miami Miller School of Medicine’s Bascom Palmer Eye Institute, is advancing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a non-invasive treatment for infectious keratitis, leveraging light-based technology and addressing antimicrobial resistance to improve outcomes for patients with severe eye infections globally.
EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.
Research was based on results of a double-blinded, randomized, clinical trial performed between November 2017 and December 2022 in the strabismus clinic of Farabi Eye Hospital.
Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating glaucoma, particularly in conjunction with cataract surgery.
In an interview with Ophthalmology Times, Alon Kahana, MD, PhD, discusses interleukin-6 and its role in autoimmune diseases, particularly thyroid eye disease, noting that a promising alternative under clinical trial is pacibekitumab, an IL-6 ligand-blocking antibody.
According to the partners, glaucoma research to be led by internationally renowned glaucoma surgeon Ike Ahmed, MD, FRCSC, distinguished research scientist Fiona McDonnell, PhD, and Ian Pitha, MD, PhD, associate director of the Alan S. Crandall Center for Glaucoma Innovation
